Louis J Aronne il 12/05/2025

Tirzepatide as Compared with Semaglutide for the Treatment of Obesity

N Engl J Med. 2025 May 11. doi: 10.1056/NEJMoa2416394. Online ahead of print.ABSTRACTBACKGROUND: Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 diabetes

Global Cardiovascular Risk Consortium il 31/03/2025

Global Effect of Cardiovascular Risk Factors on Lifetime Estimates

N Engl J Med. 2025 Mar 30. doi: 10.1056/NEJMoa2415879. Online ahead of print.ABSTRACTBACKGROUND: Five risk factors account for approximately 50% of the global burden of cardiovascular disease. How the presence or absence of classic risk factors affects lifetime estimates of cardiovascular disease an

Darren K McGuire il 31/03/2025

Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes

N Engl J Med. 2025 Mar 29. doi: 10.1056/NEJMoa2501006. Online ahead of print.ABSTRACTBACKGROUND: The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk. An assessment of the cardiova

Sergio Raposeiras-Roubin il 31/03/2025

Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation

N Engl J Med. 2025 Apr 10;392(14):1396-1405. doi: 10.1056/NEJMoa2500366. Epub 2025 Mar 29.ABSTRACTBACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of heart-failure admission among high-risk patients. However, most patients with valvular heart disease, including those und

Yogish C Kudva il 19/03/2025

A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes

N Engl J Med. 2025 May 8;392(18):1801-1812. doi: 10.1056/NEJMoa2415948. Epub 2025 Mar 19.ABSTRACTBACKGROUND: Automated insulin delivery (AID) systems have been shown to be beneficial for patients with type 1 diabetes, but data are needed from randomized, controlled trials regarding their role in the

Tatsuo Kawai il 10/02/2025

Xenotransplantation of a Porcine Kidney for End-Stage Kidney Disease

N Engl J Med. 2025 May 15;392(19):1933-1940. doi: 10.1056/NEJMoa2412747. Epub 2025 Feb 7.ABSTRACTXenotransplantation offers a potential solution to the organ shortage crisis. A 62-year-old hemodialysis-dependent man with long-standing diabetes, advanced vasculopathy, and marked dialysis-access chall

Yufang Bi il 18/11/2024

Intensive Blood-Pressure Control in Patients with Type 2 Diabetes

N Engl J Med. 2025 Mar 27;392(12):1155-1167. doi: 10.1056/NEJMoa2412006. Epub 2024 Nov 16.ABSTRACTBACKGROUND: Effective targets for systolic blood-pressure control in patients with type 2 diabetes are unclear.METHODS: We enrolled patients 50 years of age or older with type 2 diabetes, elevated systo

Ania M Jastreboff il 13/11/2024

Tirzepatide for Obesity Treatment and Diabetes Prevention

N Engl J Med. 2025 Mar 6;392(10):958-971. doi: 10.1056/NEJMoa2410819. Epub 2024 Nov 13.ABSTRACTBACKGROUND: Obesity is a chronic disease and causal precursor to myriad other conditions, including type 2 diabetes. In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown to provide substan

Gerald F Watts il 03/09/2024

Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk

N Engl J Med. 2025 Jan 9;392(2):127-137. doi: 10.1056/NEJMoa2409368. Epub 2024 Sep 2.ABSTRACTBACKGROUND: Persistent chylomicronemia is a genetic recessive disorder that is classically caused by familial chylomicronemia syndrome (FCS), but it also has multifactorial causes. The disorder is associated

Nora Makary il 21/08/2024

Diabetes-Associated Scleredema

No abstractN Engl J Med. 2024 Aug 22;391(8):e15. doi: 10.1056/NEJMicm2400802.NO ABSTRACTPMID:39167810 | DOI:10.1056/NEJMicm2400802